Patent classifications
C07D285/16
THIADIAZINE DERIVATIVES
The invention relates to thiadiazine derivatives, or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof, as well as to pharmaceutical compositions containing them and to their use as modulators of 7 nicotinic acetylcholine receptor activity in a mammalian subject. Formula (I):
##STR00001##
THIADIAZINE DERIVATIVES
The invention relates to thiadiazine derivatives, or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof, as well as to pharmaceutical compositions containing them and to their use as modulators of 7 nicotinic acetylcholine receptor activity in a mammalian subject. Formula (I):
##STR00001##
IONIC LIQUID, LUBRICANT, AND MAGNETIC RECORDING MEDIUM
A lubricant including an ionic liquid, which includes a conjugate acid (B.sup.+) and a conjugate base (X.sup.), and is protic, wherein the ionic liquid is represented by the following general formula (1):
##STR00001##
where R.sup.1 and R.sup.2 each represent a hydrogen atom or R.sup.1 and R.sup.2 form a benzene ring together with carbon atoms to which R.sup.1 and R.sup.2 are bonded, and R.sup.3 represents a straight-chain hydrocarbon group having 10 or more carbon atoms in the general formula (1).
IONIC LIQUID, LUBRICANT, AND MAGNETIC RECORDING MEDIUM
A lubricant including an ionic liquid, which includes a conjugate acid (B.sup.+) and a conjugate base (X.sup.), and is protic, wherein the ionic liquid is represented by the following general formula (1):
##STR00001##
where R.sup.1 and R.sup.2 each represent a hydrogen atom or R.sup.1 and R.sup.2 form a benzene ring together with carbon atoms to which R.sup.1 and R.sup.2 are bonded, and R.sup.3 represents a straight-chain hydrocarbon group having 10 or more carbon atoms in the general formula (1).
IONIC LIQUID, LUBRICANT, AND MAGNETIC RECORDING MEDIUM
A lubricant including: an ionic liquid, which includes a conjugate acid (B.sup.+) and a conjugate base (X.sup.), and is protic, wherein the ionic liquid is represented by the following general formula (1), and wherein the conjugate base is a conjugate base of sulfonic acid, a conjugate base of sulfonimide, or a conjugate base of trisulfonylmethide:
##STR00001##
where R.sup.1 and R.sup.2 each represent a hydrogen atom or R.sup.1 and R.sup.2 form a benzene ring together with carbon atoms to which R.sup.1 and R.sup.2 are bonded, R.sup.3 represents a to straight-chain hydrocarbon group having 10 or more carbon atoms, and R.sup.4 represents a hydrogen atom or a hydrocarbon group in the general formula (1).
IONIC LIQUID, LUBRICANT, AND MAGNETIC RECORDING MEDIUM
A lubricant including: an ionic liquid, which includes a conjugate acid (B.sup.+) and a conjugate base (X.sup.), and is protic, wherein the ionic liquid is represented by the following general formula (1), and wherein the conjugate base is a conjugate base of sulfonic acid, a conjugate base of sulfonimide, or a conjugate base of trisulfonylmethide:
##STR00001##
where R.sup.1 and R.sup.2 each represent a hydrogen atom or R.sup.1 and R.sup.2 form a benzene ring together with carbon atoms to which R.sup.1 and R.sup.2 are bonded, R.sup.3 represents a to straight-chain hydrocarbon group having 10 or more carbon atoms, and R.sup.4 represents a hydrogen atom or a hydrocarbon group in the general formula (1).
COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
Covalent inhibitors of KRAS G12C
Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.
Covalent inhibitors of KRAS G12C
Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.
Substituted thiadiazinone dioxide and preparation method therefor, herbicidal composition, and application therefor
The invention relates to the field of pesticide technology, and in particular a type of substituted thiadiazinone dioxide, preparation method, herbicidal composition and application thereof. The substituted thiadiazinone dioxide, as shown in general formula I: ##STR00001## wherein, R.sub.1 and R.sub.2 each independently represent hydrogen, cyano or alkyl with or without halogen and so on; X represents hydrogen or halogen; Y represents CZ or N; Z represents hydrogen or halogen; and when X represents halogen, Z represents hydrogen. The compound has excellent herbicidal activity against gramineous weeds, broadleaf weeds or amaranthaceous weeds, and has high selectivity for crops such as soybean, corn, rice or wheat.